Actinium Cost Of Revenue vs Net Income From Continuing Ops Analysis

ATNM Stock

USD 1.29 0.01 0.77%

Actinium Pharmaceuticals financial indicator trend analysis is way more than just evaluating Actinium Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Actinium Pharmaceuticals is a good investment. Please check the relationship between Actinium Pharmaceuticals Cost Of Revenue and its Net Income From Continuing Ops accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Actinium Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in Actinium Stock, please use our How to Invest in Actinium Pharmaceuticals guide.

Cost Of Revenue vs Net Income From Continuing Ops

Cost Of Revenue vs Net Income From Continuing Ops Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Actinium Pharmaceuticals Cost Of Revenue account and Net Income From Continuing Ops. At this time, the significance of the direction appears to have pay attention.

The correlation between Actinium Pharmaceuticals' Cost Of Revenue and Net Income From Continuing Ops is -0.79. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Net Income From Continuing Ops in the same time period over historical financial statements of Actinium Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Actinium Pharmaceuticals' Cost Of Revenue and Net Income From Continuing Ops is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of Actinium Pharmaceuticals are associated (or correlated) with its Net Income From Continuing Ops. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income From Continuing Ops has no effect on the direction of Cost Of Revenue i.e., Actinium Pharmaceuticals' Cost Of Revenue and Net Income From Continuing Ops go up and down completely randomly.

Correlation Coefficient

-0.79

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Cost Of Revenue

Cost of Revenue is found on Actinium Pharmaceuticals income statement and represents the costs associated with goods and services Actinium Pharmaceuticals provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Net Income From Continuing Ops

Most indicators from Actinium Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Actinium Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Actinium Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in Actinium Stock, please use our How to Invest in Actinium Pharmaceuticals guide.At this time, Actinium Pharmaceuticals' Selling General Administrative is very stable compared to the past year. As of the 11th of December 2024, Issuance Of Capital Stock is likely to grow to about 24.8 M, while Enterprise Value Over EBITDA is likely to drop (1.24).

Actinium Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Property Plant And Equipment Net	Current Deferred Revenue	Non Current Assets Total	Other Current Assets	Property Plant And Equipment Gross	Short Term Debt	Property Plant Equipment	Net Tangible Assets	Retained Earnings Total Equity
Total Assets		0.79	-0.56	0.52	0.86	-1.0	-0.87	0.85	1.0	1.0	-0.51	0.95	0.78	0.91	0.8	1.0	-0.46	0.85	0.75	0.84	0.82	0.83	0.86	0.83	0.96	-0.85
Short Long Term Debt Total	0.79		-0.38	0.49	0.44	-0.76	-0.81	0.84	0.78	0.78	-0.23	0.84	0.92	0.79	0.93	0.78	-0.16	0.98	0.87	0.98	0.57	0.96	0.9	0.96	0.71	-0.72
Other Current Liab	-0.56	-0.38		0.29	-0.53	0.56	0.35	-0.38	-0.56	-0.56	0.33	-0.52	-0.46	-0.41	-0.37	-0.56	0.3	-0.46	-0.43	-0.45	-0.45	-0.44	-0.42	-0.46	-0.61	0.41
Total Current Liabilities	0.52	0.49	0.29		0.41	-0.53	-0.58	0.59	0.52	0.52	-0.27	0.46	0.43	0.55	0.54	0.52	-0.27	0.46	0.4	0.45	0.53	0.46	0.44	0.43	0.39	-0.46
Total Stockholder Equity	0.86	0.44	-0.53	0.41		-0.89	-0.69	0.63	0.87	0.87	-0.46	0.71	0.37	0.75	0.4	0.87	-0.47	0.51	0.34	0.51	0.83	0.46	0.62	0.47	0.83	-0.78
Net Debt	-1.0	-0.76	0.56	-0.53	-0.89		0.85	-0.83	-1.0	-1.0	0.51	-0.93	-0.75	-0.9	-0.77	-1.0	0.47	-0.82	-0.72	-0.81	-0.83	-0.8	-0.83	-0.8	-0.95	0.84
Retained Earnings	-0.87	-0.81	0.35	-0.58	-0.69	0.85		-0.94	-0.86	-0.86	0.31	-0.89	-0.72	-0.99	-0.76	-0.86	0.26	-0.84	-0.66	-0.87	-0.76	-0.81	-0.88	-0.83	-0.88	0.95
Accounts Payable	0.85	0.84	-0.38	0.59	0.63	-0.83	-0.94		0.84	0.84	-0.27	0.85	0.78	0.92	0.81	0.84	-0.22	0.84	0.69	0.87	0.76	0.83	0.8	0.82	0.8	-0.91
Cash	1.0	0.78	-0.56	0.52	0.87	-1.0	-0.86	0.84		1.0	-0.51	0.94	0.77	0.91	0.79	1.0	-0.46	0.85	0.75	0.83	0.82	0.82	0.85	0.82	0.96	-0.84
Cash And Short Term Investments	1.0	0.78	-0.56	0.52	0.87	-1.0	-0.86	0.84	1.0		-0.51	0.94	0.77	0.91	0.79	1.0	-0.46	0.85	0.75	0.83	0.82	0.82	0.85	0.82	0.96	-0.84
Common Stock Total Equity	-0.51	-0.23	0.33	-0.27	-0.46	0.51	0.31	-0.27	-0.51	-0.51		-0.45	-0.35	-0.3	-0.36	-0.51	0.99	-0.33	-0.37	-0.29	-0.46	-0.32	-0.35	-0.33	-0.52	0.29
Common Stock Shares Outstanding	0.95	0.84	-0.52	0.46	0.71	-0.93	-0.89	0.85	0.94	0.94	-0.45		0.86	0.92	0.87	0.94	-0.38	0.92	0.85	0.9	0.72	0.92	0.91	0.92	0.95	-0.84
Non Current Liabilities Total	0.78	0.92	-0.46	0.43	0.37	-0.75	-0.72	0.78	0.77	0.77	-0.35	0.86		0.72	0.99	0.77	-0.27	0.95	0.99	0.92	0.5	0.97	0.8	0.96	0.73	-0.58
Other Stockholder Equity	0.91	0.79	-0.41	0.55	0.75	-0.9	-0.99	0.92	0.91	0.91	-0.3	0.92	0.72		0.75	0.91	-0.24	0.84	0.67	0.86	0.78	0.81	0.88	0.83	0.92	-0.95
Total Liab	0.8	0.93	-0.37	0.54	0.4	-0.77	-0.76	0.81	0.79	0.79	-0.36	0.87	0.99	0.75		0.79	-0.29	0.95	0.97	0.93	0.53	0.97	0.81	0.95	0.74	-0.61
Total Current Assets	1.0	0.78	-0.56	0.52	0.87	-1.0	-0.86	0.84	1.0	1.0	-0.51	0.94	0.77	0.91	0.79		-0.46	0.84	0.74	0.83	0.82	0.82	0.85	0.82	0.96	-0.85
Common Stock	-0.46	-0.16	0.3	-0.27	-0.47	0.47	0.26	-0.22	-0.46	-0.46	0.99	-0.38	-0.27	-0.24	-0.29	-0.46		-0.25	-0.29	-0.22	-0.45	-0.24	-0.28	-0.25	-0.47	0.24
Property Plant And Equipment Net	0.85	0.98	-0.46	0.46	0.51	-0.82	-0.84	0.84	0.85	0.85	-0.33	0.92	0.95	0.84	0.95	0.84	-0.25		0.92	0.99	0.6	0.98	0.94	1.0	0.82	-0.75
Current Deferred Revenue	0.75	0.87	-0.43	0.4	0.34	-0.72	-0.66	0.69	0.75	0.75	-0.37	0.85	0.99	0.67	0.97	0.74	-0.29	0.92		0.88	0.44	0.96	0.77	0.94	0.72	-0.5
Non Current Assets Total	0.84	0.98	-0.45	0.45	0.51	-0.81	-0.87	0.87	0.83	0.83	-0.29	0.9	0.92	0.86	0.93	0.83	-0.22	0.99	0.88		0.59	0.96	0.93	0.98	0.8	-0.79
Other Current Assets	0.82	0.57	-0.45	0.53	0.83	-0.83	-0.76	0.76	0.82	0.82	-0.46	0.72	0.5	0.78	0.53	0.82	-0.45	0.6	0.44	0.59		0.58	0.7	0.57	0.79	-0.78
Property Plant And Equipment Gross	0.83	0.96	-0.44	0.46	0.46	-0.8	-0.81	0.83	0.82	0.82	-0.32	0.92	0.97	0.81	0.97	0.82	-0.24	0.98	0.96	0.96	0.58		0.88	0.99	0.79	-0.7
Short Term Debt	0.86	0.9	-0.42	0.44	0.62	-0.83	-0.88	0.8	0.85	0.85	-0.35	0.91	0.8	0.88	0.81	0.85	-0.28	0.94	0.77	0.93	0.7	0.88		0.93	0.86	-0.83
Property Plant Equipment	0.83	0.96	-0.46	0.43	0.47	-0.8	-0.83	0.82	0.82	0.82	-0.33	0.92	0.96	0.83	0.95	0.82	-0.25	1.0	0.94	0.98	0.57	0.99	0.93		0.81	-0.72
Net Tangible Assets	0.96	0.71	-0.61	0.39	0.83	-0.95	-0.88	0.8	0.96	0.96	-0.52	0.95	0.73	0.92	0.74	0.96	-0.47	0.82	0.72	0.8	0.79	0.79	0.86	0.81		-0.85
Retained Earnings Total Equity	-0.85	-0.72	0.41	-0.46	-0.78	0.84	0.95	-0.91	-0.84	-0.84	0.29	-0.84	-0.58	-0.95	-0.61	-0.85	0.24	-0.75	-0.5	-0.79	-0.78	-0.7	-0.83	-0.72	-0.85

Click cells to compare fundamentals

Actinium Pharmaceuticals Account Relationship Matchups

Actinium Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	11.7M	66.4M	80.4M	114.2M	81.4M	85.5M
Short Long Term Debt Total	1.4M	738K	310K	2.6M	2.1M	2.2M
Other Current Liab	4.6M	(427K)	691K	(498K)	(541K)	(514.0K)
Total Current Liabilities	5.3M	4.8M	6.8M	10.6M	8.5M	4.7M
Total Stockholder Equity	5.6M	61.3M	73.5M	66.5M	36.4M	18.5M
Net Debt	(7.8M)	(62.8M)	(77.5M)	(106.3M)	(74.6M)	(70.8M)
Retained Earnings	(208.8M)	(231.0M)	(255.7M)	(288.8M)	(337.6M)	(320.7M)
Accounts Payable	4.6M	4.3M	5.5M	10.1M	8.0M	8.4M
Cash	9.3M	63.6M	77.8M	108.9M	76.7M	80.5M
Cash And Short Term Investments	9.3M	63.6M	77.8M	108.9M	76.7M	80.5M
Common Stock Total Equity	115.7K	164.7K	18K	22K	25.3K	24.0K
Common Stock Shares Outstanding	5.0M	12.1M	20.6M	24.1M	26.6M	27.9M
Liabilities And Stockholders Equity	11.7M	66.4M	80.4M	114.2M	81.4M	85.5M
Non Current Liabilities Total	682.3K	311K	3K	37.1M	36.6M	38.4M
Other Stockholder Equity	214.2M	292.3M	329.3M	355.2M	373.9M	392.6M
Total Liab	6.0M	5.1M	6.8M	47.7M	45.1M	47.3M
Total Current Assets	10.1M	64.9M	79.7M	110.9M	78.3M	82.2M
Common Stock	164.7K	18K	22K	26K	28K	54.5K
Property Plant And Equipment Net	1.1M	1.0M	639K	2.9M	2.9M	3.0M
Current Deferred Revenue	(4.6M)	(4.3M)	998K	35M	40.3M	42.3M
Non Current Assets Total	1.6M	1.5M	639K	3.3M	3.2M	3.3M
Other Current Assets	833.8K	1.4M	1.9M	2.0M	1.6M	1.2M
Property Plant And Equipment Gross	1.1M	312K	974K	3.4M	3.6M	3.7M
Short Term Debt	745.8K	854K	614K	996K	1.1M	1.1M
Property Plant Equipment	1.1M	1.0M	639K	2.9M	3.4M	3.6M
Net Tangible Assets	5.6M	61.3M	73.5M	66.5M	76.5M	80.3M
Retained Earnings Total Equity	(186.9M)	(208.8M)	(231.0M)	(255.7M)	(230.2M)	(241.7M)
Capital Surpluse	195.6M	214.2M	292.3M	329.3M	378.7M	201.8M
Non Currrent Assets Other	49.9K	50K	(639K)	302K	313K	328.7K
Other Assets	441.0K	441.2K	1.2M	302K	1.0	0.95
Net Invested Capital	6.0M	61.3M	73.5M	66.5M	36.4M	41.9M
Net Working Capital	4.7M	60.2M	72.9M	100.3M	69.8M	51.8M
Capital Lease Obligations	1.0M	738K	310K	2.6M	2.1M	1.2M
Capital Stock	164.7K	18K	22K	26K	28K	49.9K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Actinium Pharmaceuticals is a strong investment it is important to analyze Actinium Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Actinium Pharmaceuticals' future performance. For an informed investment choice regarding Actinium Stock, refer to the following important reports:

How To Invest In Actinium

Details

Is Actinium Stock a good investment?

Details

What is Actinium Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Actinium Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in Actinium Stock, please use our How to Invest in Actinium Pharmaceuticals guide.

You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Actinium Pharmaceuticals. If investors know Actinium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Actinium Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.39)

Revenue Per Share

0.003

Quarterly Revenue Growth

(1.00)

Return On Assets

(0.31)

Return On Equity

(0.88)

The market value of Actinium Pharmaceuticals is measured differently than its book value, which is the value of Actinium that is recorded on the company's balance sheet. Investors also form their own opinion of Actinium Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Actinium Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Actinium Pharmaceuticals' market value can be influenced by many factors that don't directly affect Actinium Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Actinium Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Actinium Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Actinium Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Actinium Cost Of Revenue vs Net Income From Continuing Ops Analysis

Cost Of Revenue vs Net Income From Continuing Ops

Cost Of Revenue vs Net Income From Continuing Ops Correlation Analysis

Correlation Coefficient

Cost Of Revenue

Net Income From Continuing Ops

Actinium Pharmaceuticals fundamental ratios Correlations

Actinium Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Actinium Pharmaceuticals fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments

Total Current Assets	- 1.0	Net Debt
Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Net Debt	- 1.0	Total Assets
Other Stockholder Equity	- 0.99	Retained Earnings
Retained Earnings Total Equity	- 0.95	Other Stockholder Equity